Loading stock…

Ascendis Pharma A/S (ASND) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

ASNDAscendis Pharma A/S

Revenue FY25$381M

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+149%10

Revenue, next 1Y+82%10

Revenue, next 3Y, CAGR+52%10

Revenue, next 5Y, CAGR+36%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-36%2

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 149%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 52%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 36%/yr over five years.10/10

WATCH

Revenue grew 149%/yr over the last 3 years; forecasts see it cooling to 52%/yr.

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 52%/yr).

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

ASNDAscendis Pharma A/S

Total return Current1134%

Price return Current1134%

MOMENTUM RATING↗

VERY WEAK12 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-16%1

3-month return-15%2

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high80%5

1-year return-8%4

3-year return-8%2

5-year return-8%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 8% over the past year, now 20% below its 52-week high. That is right in line with the market.

Returns sit at the market level so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.9% over three years and -7.9% over five), behind 70% of the market.

The stock is underperforming over the past month (-16%) and over three months (-15%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Ascendis Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ASNDAscendis Pharma A/S

Revenue FY25$381M

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+149%10

Revenue, next 1Y+82%10

Revenue, next 3Y, CAGR+52%10

Revenue, next 5Y, CAGR+36%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-36%2

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 149%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 52%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 36%/yr over five years.10/10

WATCH

Revenue grew 149%/yr over the last 3 years; forecasts see it cooling to 52%/yr.

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about 0%/yr vs revenue 52%/yr).

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

ASNDAscendis Pharma A/S

Total return Current1134%

Price return Current1134%

MOMENTUM RATING↗

VERY WEAK12 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-16%1

3-month return-15%2

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high80%5

1-year return-8%4

3-year return-8%2

5-year return-8%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 8% over the past year, now 20% below its 52-week high. That is right in line with the market.

Returns sit at the market level so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.9% over three years and -7.9% over five), behind 70% of the market.

The stock is underperforming over the past month (-16%) and over three months (-15%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Ascendis Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Ascendis Pharma A/S

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Ascendis Pharma. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Ascendis Pharma. Get the full investment case.

Premium